PTC Therapeutics vs Ultragenyx Pharmaceutical
PTCT and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTCT and RARE compare
PTC Therapeutics is the larger company, worth 3.1 times as much as Ultragenyx Pharmaceutical ($5.0B against $1.6B).
Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus −35.1% for PTC Therapeutics).
PTC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −9.2% compared with −81.7% at Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTCT | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $1.6B |
| Share price | $60.36 | $16.70 |
| Change, 1 year | −19.8% | −49.5% |
| Change, 5 years | 58.6% | −78.2% |
| Beta (5Y) | 1.09 | 2.12 |
| Employees | 991 | 1,371 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.4× | 2.3× (better) |
| EV/EBITDA | 16.5× | – |
| P/FCF | 2440× | – |
| FCF yield | 0.04% (better) | −29.7% |
| Fair value | $47.05 | – |
| Margin of safety | −28.3% | – |
| Growth | ||
| Revenue growth (TTM) | −35.1% | 17.5% (better) |
| Revenue growth, 5Y average | 35.4% (better) | 19.9% |
| Net income growth (TTM) | −114% | – |
| EPS growth (TTM) | −114% | – |
| Profitability | ||
| Operating margin | 12.8% (better) | −73.6% |
| Net margin | −9.2% (better) | −81.7% |
| FCF margin | 0.18% (better) | −68.2% |
| Financial health | ||
| Net debt / EBITDA | −7.63 | – |
| Current ratio | 3.27 (better) | 1.73 |
| Altman Z-score | 0.78 (better) | −5.26 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 120% | 108% |
| Held by insiders | 3.0% | 4.0% |
| Insider net buying, 12 months | −$44.2M | −$3.8M (better) |
| Short interest, % of float | 9.6% | 25.0% |
Go deeper
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.